Head and neck cancer
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Who can joinAdults
Age60+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine and radiation
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
5 hospitals in India taking patients for this trial.
M S Ramaiah Memorial HospitalBangaloreDirections ↗
Tata Memorial HospitalMumbaiDirections ↗
HealthCare Global HCG Manavata Cancer CentreNashikDirections ↗
Rajiv Gandhi Cancer Institute and Research CentreNew DelhiDirections ↗
HCG cancer centerVijayawadaDirections ↗
Registry summary (technical)
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT04892173 on ClinicalTrials.gov
Last updated on the registry 25 Sep 2026 · read by us 20 Oct 2026